

2-6 dinsdagochtend 09.00–12.00 (180 min) – Uro

Wandelen met een strandjutter 07:00 - 08:45u



09.00–09.10 Inleiding

Spreker	Onderwerp	Sessie	Titel
Do-Youn Oh	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Oral Abstract Session	Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).
Lin Shen	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Rapid Oral Abstract Session	Neoadjuvant/adjuvant serplulimab vs placebo combined with chemotherapy for PD-L1-positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.
Zhihao Lu	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Oral Abstract Session	Izalontamab brengitecan versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.
Tanios Bekaii-Saab	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Rapid Oral Abstract Session	Pemigatinib for untreated unresectable/metastatic cholangiocarcinoma with FGFR2 rearrangement: Phase 3 FIGHT-302 results.
Sunnie Kim	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Oral Abstract Session	New Directions in Gastroesophageal Cancers

09.45–10.00 Discussie

10.00–10.15 Pauze

10.15–11.15 Inleiding

Spreker	Onderwerp	Sessie	Titel
Do-Youn Oh	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Education Session	Peri-Operative Treatment With Immunotherapy in Resectable Gastroesophageal Cancer
Brian Wolpin	Special Sessions	Plenary Session	Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (RASolute 302).
Jennifer Knox	Special Sessions	Plenary Session	Discussant
Ghassan Abou-Alfa	Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary	Oral Abstract Session	EMERALD-3: Tremelimumab plus durvalumab with or without lenvatinib combined with TACE in unresectable embolization-eligible HCC.

11.15–11.35 Refereren

Hanneke Wilmink

11.35–11.45 Koffie refill

11.45–12.15 Professionele ontwikkeling

Spreker	Onderwerp	Sessie	Titel
Coral Olazagasti	Medical Education and Professional Development	Rapid Oral Abstract Session	Career fulfillment and intent to leave among oncology physicians: A global survey.
Wendy Oldenmenger	Medical Education and Professional Development	Education Session	Battling the Blaze: Tools to Protect Joy and Combat Burnout.

Dinsdagmiddag 13.45–17.00 Uro

13.45–14.45 Inleiding

Spreker	Onderwerp	Sessie	Titel
Thomas Powles	Genitourinary Cancer – Kidney and Bladder	Oral Abstract Session	Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma: 3.5-year follow-up and response analyses from EV-302.
Gopa Iyer	Genitourinary Cancer – Kidney and Bladder	Oral Abstract Session	Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4.
Mary-Ellen Taplin	Special Sessions	Plenary Session	PROTEUS: Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized/locally advanced prostate cancer.
Declan Murphy	Special Sessions	Plenary Session	Discussion of LBA1.

14.45–15.00 Discussie & Pauze

15.00–16.00 Inleiding

Spreker	Onderwerp	Sessie	Titel
Neeraj Agarwal	Genitourinary Cancer – Prostate, Testicular, and Penile	Oral Abstract Session	TALAPRO-3: Talazoparib + enzalutamide versus placebo + enzalutamide in mCSPC with HRR alterations.
Joaquin Mateo	Genitourinary Cancer – Prostate, Testicular, and Penile	Oral Abstract Session	Final results from ZZFIRST: Enzalutamide and talazoparib in metastatic hormone-naïve prostate cancer.
Atish Choudhury	Genitourinary Cancer – Prostate, Testicular, and Penile	Oral Abstract Session	A-DREAM: ADT interruption in exceptional responders with metastatic hormone-sensitive prostate cancer.

Toni Choueiri Genitourinary Cancer – Kidney and Bladder Oral Abstract Session

ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in KEYNOTE-564.

Darren Feldman Genitourinary Cancer – Kidney and Bladder Rapid Oral Abstract Session

Final results of cabozantinib plus nivolumab in non-clear cell renal cell carcinoma.

16.00–16.20 Refereren

Michel van Kruchten

16.20–16.30 Pauze

16.30–17.00 Quiz